Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1B STUDY OF PF-05082566 IN COMBINATION WITH MOGAMULIZUMAB (KW-0761) IN PATIENTS WITH ADVANCED SOLID TUMORS

NCT02444793 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02444793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02444793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1B STUDY OF PF-05082566 IN COMBINATION WITH MOGAMULIZUMAB (KW-0761) IN PATIENTS WITH ADVANCED SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2015
Completion date
October 31, 2017
Enrollment
24 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic solid tumors